Skip to main content

Table 1 Brief chronology of the key clinical events in this case

From: Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma

Time before and after

CAR T cell therapy

Date

Key events

−5 years

2014/7

Diagnosis of DLBCL

−5 to −0.5 years

2014/7 to 2018/1

8 cycles of R-CHOP and sustained remission

−1 year

2017/7

Discontinuation of entecavir

−6 months

2018/1

Relapse/reintroduction of entecavir

−4 days to −2 days

2018/6/29 to 2018/7/1

Standard lymphodepleting chemotherapy regimen

0 days

2018/7/3

Start of CART therapy

0 days to + 3 days

2018/7/3 to 2018/7/6

Sequential infusion of anti-CD 19 and anti-CD22 CAR T cell therapy

+ 4 weeks

2018/8/4

Discontinuation of entecavir

+ 9 weeks

2018/9/4

Activation of hepatitis B

+ 3.3 months

2018/10/12

Death